Skip to main content
. Author manuscript; available in PMC: 2022 Feb 6.
Published in final edited form as: Cancer Prev Res (Phila). 2021 Apr 23;14(7):729–740. doi: 10.1158/1940-6207.CAPR-20-0303

Figure 1.

Figure 1.

Distribution of oncology markers showing the top three significant miRNAs between stage II PDAC cases and controls with FDR<0.1 in the TexGen cohort.